Earnings History Data for Viridian Therapeutics (VRDN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Viridian Therapeutics

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
27-02-2024	PM		VRDN	Viridian Therapeutics	987.00	-1.35	-1.08	0.00	Viridian Therapeutics GAAP EPS of -$1.35 [2/28/2024 1:29 AM]	20.14	0.54 (2.73%)	19.80	0.19 (0.97%)	10.93 - 33.51	1,718,938	780,000	501
Viridian Therapeutics GAAP EPS of -$1.35 [2/28/2024 1:29 AM]
13-11-2023	PM		VRDN	Viridian Therapeutics, Inc.	593.48	-1.09	-1.22	-0.86	Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $0.03M [11/14/2023 1:33 AM]	15.18	1.19 (8.47%)	14.30	0.31 (2.22%)	10.93 - 39.00	1,112,859	960,000	886
Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $0.03M [11/14/2023 1:33 AM]
08-08-2023	AH		VRDN	Viridian Therapeutics	815.00	-1.27	-1.26	0.00	Viridian Therapeutics GAAP EPS of -$1.27 in-line, revenue of $0.07M misses by $0.13M [8/8/2023 5:21 PM]	19.29	0.54 (2.88%)	18.38	-0.37 (-1.97%)	13.45 - 39.00	742,893	670,000	1,625
Viridian Therapeutics GAAP EPS of -$1.27 in-line, revenue of $0.07M misses by $0.13M [8/8/2023 5:21 PM]
09-05-2023	AH	After the close (May 9)	VRDN	Viridian Therapeutics, Inc.	1,130	-1.61	1.00	-0.98	Viridian Therapeutics GAAP EPS of -$1.61 misses by $0.59, revenue of $0.1M in-line [5/9/2023 4:58 PM]	25.36	-0.32 (-1.25%)	24.60	-1.08 (-4.21%)	9.66 - 39.00	845,802	610,000	12,229
Viridian Therapeutics GAAP EPS of -$1.61 misses by $0.59, revenue of $0.1M in-line [5/9/2023 4:58 PM]
08-03-2023	PM	7:00 AM ET (Mar 8)	VRDN	Viridian Therapeutics, Inc.	1,320	-1.13	-0.72	-1.32	Viridian Therapeutics GAAP EPS of -$1.13 misses by $0.40, revenue of $0.1M misses by $0.36M [3/8/2023 7:02 AM]	29.43	-3.49 (-10.60%)	31.41	-1.51 (-4.59%)	9.47 - 39.00	1,429,926	410,000	12,757
Viridian Therapeutics GAAP EPS of -$1.13 misses by $0.40, revenue of $0.1M misses by $0.36M [3/8/2023 7:02 AM]
14-11-2022	PM	7:00 AM ET (Nov 14)	VRDN	Viridian Therapeutics, Inc.	789.80	-0.86	-0.87	-1.25	Viridian Therapeutics GAAP EPS of -$0.86 beats by $0.12, revenue of $1.19M beats by $0.93M [11/14/2022 7:12 AM]	20.27	-0.24 (-1.15%)	20.51	0.0 (0.00%)	9.47 - 26.22	789,198	410,000	16,294
Viridian Therapeutics GAAP EPS of -$0.86 beats by $0.12, revenue of $1.19M beats by $0.93M [11/14/2022 7:12 AM] Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) [Nov-14-22 06:59AM]
15-08-2022	PM	7:00 AM ET (Aug 15)	VRDN	Viridian Therapeutics, Inc.	362.22	-1.06	-0.86	-2.21	Viridian Therapeutics GAAP EPS of -$1.06 misses by $0.17, revenue of $0.26M beats by $0.03M [8/15/2022 7:05 AM]	21.91	7.18 (48.74%)	19.18	4.45 (30.21%)	9.47 - 25.38	11,710,629	350,000	834,896
Viridian Therapeutics GAAP EPS of -$1.06 misses by $0.17, revenue of $0.26M beats by $0.03M [8/15/2022 7:05 AM] Viridian stock soars 39% as thyroid eye disease drug shows promise in trial [8/15/2022 8:02 AM] Viridian hits 52-week high on data for thyroid eye disease candidate [8/15/2022 1:52 PM] Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates [Aug-15-22 07:02AM] Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) [Aug-15-22 06:59AM]
12-05-2022	AH	4:05 PM ET (May 12)	VRDN	Viridian Therapeutics, Inc.	289.90	-0.98	-0.92	-2.91	Viridian Therapeutics GAAP EPS of $0.98, revenue of $0.22M [5/12/2022 4:20 PM]	13.51	2.95 (27.94%)	10.56	0.0 (0.00%)	9.47 - 22.00	387,598	320,000	588
Viridian Therapeutics GAAP EPS of $0.98, revenue of $0.22M [5/12/2022 4:20 PM] Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates [May-12-22 04:05PM]
10-03-2022	AH	4:05 PM ET (Mar 10)	VRDN	Viridian Therapeutics, Inc.	392.09	-1.32	-1.15	-5.31	Viridian Therapeutics GAAP EPS of -$1.32, revenue of $0.21M [3/10/2022 4:12 PM]	20.29	1.25 (6.57%)	0.0	0.0 (0.00%)	10.44 - 22.00	101,838	130,000	0
Viridian Therapeutics GAAP EPS of -$1.32, revenue of $0.21M [3/10/2022 4:12 PM] Strong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of five-year loss [Mar-10-22 10:33AM] Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates [Mar-10-22 04:05PM]
04-11-2021	AH		VRDN	Viridian Therapeutics	168.00	-1.25	-1.19	0.00	Viridian Therapeutics reports Q3 results [11/4/2021 5:36 PM]	18.86	0.77 (4.26%)	0.0	0.0 (0.00%)	10.44 - 25.67	81,915	80,000	0
Viridian Therapeutics reports Q3 results [11/4/2021 5:36 PM] Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates [Nov-04-21 04:05PM] Viridian Therapeutics to Present at Upcoming Investor Conferences [Nov-03-21 04:05PM]
06-05-2021	AH	4:05 PM ET (May 6)	VRDN	Viridian Therapeutics, Inc.	0.00	-2.91	-0.61	0.00	Viridian Therapeutics reports Q1 results [5/6/2021 5:12 PM]	17.53	0.17 (0.98%)	0.0	0.0 (0.00%)	7.08 - 25.67	5,457	60,000	0
Viridian Therapeutics reports Q1 results [5/6/2021 5:12 PM] Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates [May-06-21 04:05PM]
25-03-2021	AH	After the close (Mar 25)	VRDN	Viridian Therapeutics, Inc.	0.00	-5.31	-1.27	0.00	Viridian Therapeutics reports Q4 results [3/25/2021 4:38 PM]	17.97	0.70 (4.02%)	17.01	-0.26 (-1.51%)	5.54 - 25.67	51,968	20,000	130
Viridian Therapeutics reports Q4 results [3/25/2021 4:38 PM] Viridian Therapeutics, Inc. to Host Earnings Call [Mar-25-21 02:30PM] Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates [Mar-25-21 04:05PM]